Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Telaprevir

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: Telaprevir. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2006-005123-42 Sponsor Protocol Number: VX06-950-107 Start Date*: 2007-03-28
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106 Wh...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003738-18 Sponsor Protocol Number: M13-862 Start Date*: 2013-04-26
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated In...
    Medical condition: Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-007995-81 Sponsor Protocol Number: VX08-950-110 Start Date*: 2010-04-28
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2a, 2-Part, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study of Telaprevir in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Su...
    Medical condition: chronic hepatitis c virus genotype 1 infection human immunodeficiency virus genotype 1 infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    14.0 10021881 - Infections and infestations 10008919 Chronic HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004150-26 Sponsor Protocol Number: VX11-222-106 Start Date*: 2012-03-12
    Sponsor Name:Vertex Pharmaceuticals
    Full Title: A Multicenter, Open-Label, Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2 and Ribavirin) in Subjects With Genotype 1 Chronic...
    Medical condition: Chronic Hepatitis C Virus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005525-75 Sponsor Protocol Number: SSAT052 Start Date*: 2013-07-16
    Sponsor Name:St Stephen's AIDS Trust
    Full Title: An open label, randomised, pilot trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genoty...
    Medical condition: Acute hepatitis C infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004724-35 Sponsor Protocol Number: VX-950HPC3006 Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects
    Medical condition: Chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001180-53 Sponsor Protocol Number: TMC435HPC3001 Start Date*: 2012-01-06
    Sponsor Name:Janssen R&D Ireland
    Full Title: A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C gen...
    Medical condition: Hepatitis C Virus (HCV) genotype-1 infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GR (Completed) BE (Completed) ES (Completed) DE (Completed) SE (Completed) HU (Completed) AT (Completed) DK (Completed) PL (Completed) CZ (Completed) NO (Completed) GB (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-004720-20 Sponsor Protocol Number: VX07-950-108 Start Date*: 2008-07-03
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C
    Medical condition: Chronic Hepatitis C, Genotype 1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001044-44 Sponsor Protocol Number: VX-950-TiDP24-C208 Start Date*: 2007-08-01
    Sponsor Name:Tibotec BVBA
    Full Title: A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys®) and ribavirin (Copegus®) or Peg-IFN alfa2...
    Medical condition: Hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003836-39 Sponsor Protocol Number: VX08-950-111 Start Date*: 2008-11-16
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response...
    Medical condition: Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004695-11 Sponsor Protocol Number: AI452-020 Start Date*: 2013-06-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic He...
    Medical condition: Chronic Hepatitis C Virus (HCV) Infection (Genotype-1)
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) CZ (Completed) GB (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004544-30 Sponsor Protocol Number: 1241.37 Start Date*: 2013-04-03
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pe...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Prematurely Ended) NO (Completed) IT (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) DE (Completed) DK (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005740-95 Sponsor Protocol Number: M13-389 Start Date*: 2012-08-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin ...
    Medical condition: Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    15.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) BE (Completed) NL (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004237-14 Sponsor Protocol Number: AI444-052 Start Date*: 2012-02-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C Revised Prot...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Completed) GB (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004442-15 Sponsor Protocol Number: HISTORY Start Date*: 2013-09-11
    Sponsor Name:University Leipzig
    Full Title: High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients ...
    Medical condition: High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004871 10019642 Hepatic cirrhosis NOS LLT
    16.1 100000004848 10072848 Hepatitis C virus genotype 1 positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004138-41 Sponsor Protocol Number: TEL-PR Start Date*: 2012-12-10
    Sponsor Name:AZIENDA OSPEDALIERA DI PARMA
    Full Title: Anti-viral T cell responses in patients with chronic HCV infection treated with telaprevir: can therapy induce functional T cell reconstitution?
    Medical condition: Chronic active hepatitis C never treated previously with anti-HCV therapies
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004665-33 Sponsor Protocol Number: VX06-950-106 Start Date*: 2007-04-04
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral R...
    Medical condition: Hepatitis C virus (HCV) infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005409-65 Sponsor Protocol Number: AI452-021 Start Date*: 2013-01-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatiti...
    Medical condition: Chronic Hepatitis C Virus Infection (Genotype 1b)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) DE (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-005323-17 Sponsor Protocol Number: AML02 Start Date*: 2014-07-24
    Sponsor Name:Erasmus MC
    Full Title: Pharmacokinetic and pharmacodynamic properties of amlodipine oral solution in the pediatric population
    Medical condition: Hypertension
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005522-29 Sponsor Protocol Number: M14-002 Start Date*: 2013-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ...
    Medical condition: Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 19:39:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA